Argus retinal prosthesis

Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System

Retrieved on: 
Tuesday, July 11, 2023
Medical Devices, Health, Science, Research, Optical, Medicine, Type 2 diabetes, Street Hassle, Orion (system-on-a-chip), Food and Drug Administration, Bangladesh Technical Education Board, Register, Motion, Investigational New Drug, Visual acuity, Patient, Observation, EFS, Visual perception, University, Therapy, Drug discovery, Brain, SAE, Security (finance), UCLA, FDA, Safety, Registration statement, Drug Quality and Security Act, COVID-19, Stroke, Argus retinal prosthesis, Annual report, Form, Obesity, Arm, Vivani, Orion, Sale, Baylor College of Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical device

Five of the initial six subjects participated in an efficacy evaluation at three years post-implantation.

Key Points: 
  • Five of the initial six subjects participated in an efficacy evaluation at three years post-implantation.
  • Two of the five subjects achieved measurable “Grating Visual Acuity,” which is an established metric of visual function.
  • Cortigent anticipates extending the EFS by one year to allow further observation of the long-term safety, reliability, and visual function provided by the Orion System.
  • There may be additional risks that the Company considers immaterial, or which are unknown and new risks emerge from time to time.

Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Retrieved on: 
Wednesday, June 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Medicine, US Foods, Type 2 diabetes, Obesity, Arm, Therapy, Vivani, Maxim, Hans Hassle, Registration statement, COVID-19, Stroke, Drug discovery, Metabolism, Sale, Register, Charles M. Vest, Argus retinal prosthesis, Investigational New Drug, Patient, Annual report, Form, Knowledge, Security (finance), FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Conference, Food, Medical device

The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.

Key Points: 
  • The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.
  • These include multiple therapeutic categories and emerging technologies, which Maxim’s presenting companies at this year’s Maxim Healthcare Conference are focused on, and for many, that includes key data-driven events in 2023.
  • Maxim Senior Analysts will host a wide range of biotechnology and medical device companies in a series of presentations and interactive discussions with CEOs and key management.
  • Maxim will also be hosting several topical industry panels that promise to be timely and engaging.

Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023

Retrieved on: 
Friday, April 21, 2023
Area studies, Health, Private law, AMD, CIR, Clinical trial, Research, ESGO, Argus retinal prosthesis, Vision, Research and development, Development, Patient, Investment, Primavera, Next Generation, FDA, Cryptocurrency, Pharmaceutical industry

Pixium Vision ended 2022 with a net cash position of €7.7 million, compared to €14.5 million at the end of 2021.

Key Points: 
  • Pixium Vision ended 2022 with a net cash position of €7.7 million, compared to €14.5 million at the end of 2021.
  • On January 12, 2023, Pixium Vision announced publication of peer-reviewed articles demonstrating the potential of the Next Generation PRIMA implant.
  • On February 13, 2023, Pixium Vision announced the termination of the convertible note financing agreement with US-based healthcare investor ESGO.
  • On March 17, 2023, Pixium Vision announced the reduction of share capital, due to losses, by reduction of nominal value: number of shares unchanged.

Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing Orion Clinical Study

Retrieved on: 
Tuesday, April 4, 2023
Research, General Health, Pharmaceutical, Optical, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, FDA, Other Science, Health, Medicine, University, Orion, Trial of the century, Bangladesh Technical Education Board, Argus retinal prosthesis, UCLA, Pharmaceutical industry

This represents the final $1 million funding of the original $6.4 million five-year grant award.

Key Points: 
  • This represents the final $1 million funding of the original $6.4 million five-year grant award.
  • Cortigent, Inc. was formed by Vivani Medical to continue the work of its Neuromodulation Division, formerly Second Sight Medical Products, Inc. Cortigent will use these funds to support the Orion clinical trial currently underway at the University of California, Los Angeles (UCLA).
  • The Orion Visual Cortical Prosthesis is being developed with the goal of providing meaningful artificial vision to profoundly blind people.
  • Based on a company-sponsored U.S. market study, the Company estimates that about 82,000 Americans are profoundly blind.

Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 31, 2023
Biotechnology, Diabetes, Medical Devices, Health, Pharmaceutical, Medicine, Second Sight, State Administrative Expenses, Vivani, Type 2 diabetes, Accounting, NPM, Development, Argus retinal prosthesis, Investigational New Drug, Patient, Form, Conditional sentence, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry, Medical device, Cryptocurrency

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product candidate NPM-119 for the treatment of patients with type 2 diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product candidate NPM-119 for the treatment of patients with type 2 diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
  • In August 2022, the business combination of Second Sight and NPM was completed, and the combined company was renamed Vivani.
  • In November 2022, Vivani’s neuromodulation business was established as a wholly-owned subsidiary named Cortigent, Inc., a Delaware corporation.
  • Net Loss: The net loss was $13.9 million in 2022, as compared to $12.8 million in 2021.

Pixium Vision announces its cash position at 31 December 2022 and provides an update on its activities

Retrieved on: 
Tuesday, February 14, 2023
CE, Journal, Area studies, Investment, EGM, Judgement, See, AMD, Patient, Clinical trial, Stanford University, Argus retinal prosthesis, Health, Neural engineering, ESGO, Pharmaceutical industry, Cryptocurrency

Until 31 December 2022, investments in fixed and intangible assets remained low leading to a net cash outflow from investment activities of €0.1 million.

Key Points: 
  • Until 31 December 2022, investments in fixed and intangible assets remained low leading to a net cash outflow from investment activities of €0.1 million.
  • In total, at 31 December 2022, Pixium Vision’s cash position amounted to €7.7 million, compared to €14.5 million on 1 January 2022.
  • On 15 December 2022, Pixium Vision announced the completion of implantations in the European pivotal trial PRIMAvera.
  • On 28 December 2022, Pixium Vision announced welcoming the judgment by Paris Commercial Court against Second Sight Medical Products.

Pixium Vision welcomes judgment by Paris Commercial Court against Second Sight Medical Products

Retrieved on: 
Wednesday, December 28, 2022
Argus retinal prosthesis, CET, Medicine, Judgement, Mnemos EP, Patient, Memorandum of understanding, US, Animal, Life insurance

Paris, France, December 28, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, today announces that the company welcomes the judgment rendered by the Paris Commercial Court in the case brought by Pixium Vision against Second Sight Medical Products, Inc. (renamed Vivani Medical, Inc.) following the latter's withdrawal from the proposed business combination between the two companies1 on April 2, 2021.

Key Points: 
  • Paris, France, December 28, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, today announces that the company welcomes the judgment rendered by the Paris Commercial Court in the case brought by Pixium Vision against Second Sight Medical Products, Inc. (renamed Vivani Medical, Inc.) following the latter's withdrawal from the proposed business combination between the two companies1 on April 2, 2021.
  • As a result, the Paris Commercial Court ordered the termination of the MoU on the grounds of Second Sight Medical Products’ sole breach.
  • Pursuant to this judgment, which may be provisionally enforced, the Paris Commercial Court granted Pixium Vision’s main claims and ordered Second Sight Medical Products to pay Pixium Vision:
    the sum of €2,000,000 for expenses Pixium Vision incurred in connection with the proposed business combination;
    the sum of €500,000 for the image and reputational damage sustained by Pixium Vision due to Second Sight Medical Products’ withdrawal from this transaction; and
    the sum of €30,000 pursuant to Article 700 of the French Code of Civil Procedure, as well as all costs of the suit.
  • Pixium Vision is pleased with the decision of the Paris Commercial Court, which is subject to appeal.

Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates

Retrieved on: 
Monday, November 14, 2022
Biotechnology, Medical Devices, Health, Pharmaceutical, Optical, GMP, Orion Bus Industries, Commission, Medicine, Diabetes, File, Kingdom Holding Company, Hans Hassle, Argus retinal prosthesis, Patient, Safety, Type 2 diabetes, Mergers and acquisitions, Security (finance), IND, Regulation of tobacco by the U.S. Food and Drug Administration, Neuromodulation, COVID-19, Death, Food, Vivani, Pharmaceutical industry, Vaccine, Airline

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), a biopharmaceutical company developing miniaturized, long-term drug implants including lead asset NPM-119 for the treatment of patients with type 2 diabetes, today announced financial results for the third quarter ending September 30, 2022 and provides business updates.

Key Points: 
  • Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), a biopharmaceutical company developing miniaturized, long-term drug implants including lead asset NPM-119 for the treatment of patients with type 2 diabetes, today announced financial results for the third quarter ending September 30, 2022 and provides business updates.
  • The merger of Second Sight Medical Products, Inc. and Nano Precision Medical, Inc. closed on August 30, 2022.
  • Research and development expenses were $3.9 million in the third quarter of 2022, compared to $2.9 million in the third quarter of 2021.
  • General and administrative expenses were $1.6 million in the third quarter of 2022, compared to $0.6 million in the third quarter of 2021.

Vivani Medical to Present at the ThinkEquity Investor Conference

Retrieved on: 
Monday, October 17, 2022
Biotechnology, Pharmaceutical, Optical, Health, Diabetes, Medical Devices, Health Technology, Clinical Trials, U.S. Securities and Exchange Commission, CFO, Argus retinal prosthesis, Time, Orion Bus Industries, Vivani, IND, Commission, Hans Hassle, Annual report, NASDAQ, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, ThinkEquity, Security (finance), Technology, Food, Mandarin Oriental Hotel Group, Company, CEO, Type 2 diabetes, EDT, Medicine, Forward-looking statement, COVID-19, Medical device, Pharmaceutical industry

Vivani Medical, Inc. (NASDAQ: VANI) (the Company or Vivani), an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic implants, announced today that it will present at the upcoming ThinkEquity investor conference at 11:00 am EDT at the Mandarin Oriental in New York on October 26, 2022.

Key Points: 
  • Vivani Medical, Inc. (NASDAQ: VANI) (the Company or Vivani), an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic implants, announced today that it will present at the upcoming ThinkEquity investor conference at 11:00 am EDT at the Mandarin Oriental in New York on October 26, 2022.
  • Dr. Adam Mendelsohn, CEO, will present a company overview and Brigid Makes, CFO, will join in hosting one-on-one meetings with investors during the conference.
  • Leveraging its proprietary NanoPortal platform, Vivani Medical develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time, with the goal of guaranteeing patient adherence to their medication.
  • Vivani represents the August 2022 merger of Second Sight Medical Products, Inc., and Nano Precision Medical, Inc. NPM-119 is being developed within Vivanis Biopharm Division (formerly Nano Precision Medical, Inc.).

Innovations and Growth Opportunities in Medical Imaging, Surgical Robot and Digital Health - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 11, 2022
Health Technology, Health, Surgery, Medical Devices, Nanotechnology, Argus retinal prosthesis, Medical imaging, Robot-assisted surgery, Medtech, Research, Digital health, Technology, Ministry of Education (Malaysia), AI, Medicine, TOE, Digital, ECG, Medical device

The "Innovations and Growth Opportunities in Medical Imaging, Surgical Robot and Digital Health" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Innovations and Growth Opportunities in Medical Imaging, Surgical Robot and Digital Health" report has been added to ResearchAndMarkets.com's offering.
  • The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) profiles a wide range of innovations from the advanced medical device and imaging industry.
  • The issue includes advanced imaging technologies such as photon-counting computed tomography, portable wireless ultrasound, AI based ECG, and digital twin for surgery planning.
  • Some of the advanced surgical robot innovations include hybrid surgical robot, ergonomic design and high definition visualization, endoscopic surgical robot.